Acute Myelogenous Leukemia in Children

Acute Myelogenous Leukemia in Children

Acute myelogenous leukemia (AML), also known as acute myeloid leukemia or acute non-lymphocytic leukemia, is a type of cancer that affects the myeloid lineage of blood cells. It is characterized by the rapid proliferation of abnormal, immature myeloid cells, which are precursors to various types of blood cells, including red blood cells, platelets, and certain types of white blood cells.

Epidemiology and Etiology

AML is relatively rare in children, accounting for approximately 15-20% of all childhood leukemias. The incidence rate of AML in children is approximately 7-8 cases per million per year. The peak incidence occurs between the ages of 1 and 4 years. AML is slightly more common in males than females.

The exact cause of AML in children is not well understood. However, several risk factors have been identified, including:

  • Genetic disorders: Certain genetic disorders, such as Down syndrome, Fanconi anemia, Bloom syndrome, and neurofibromatosis type 1, increase the risk of developing AML.
  • Environmental exposures: Exposure to ionizing radiation, certain chemotherapeutic agents, and potentially environmental toxins may increase the risk of AML.
  • Previous cancer treatment: Children who have received chemotherapy or radiation therapy for a previous cancer are at an increased risk of developing AML, particularly those who received treatment regimens involving topoisomerase II inhibitors or alkylating agents.

Pathophysiology

AML is characterized by the uncontrolled proliferation of immature myeloid cells, known as myeloblasts or leukemic blasts, in the bone marrow and blood. These cells fail to mature and develop into functional blood cells, leading to a disruption in the normal production of red blood cells, platelets, and normal white blood cells.

The accumulation of leukemic blasts in the bone marrow can lead to a variety of complications, including:

  • Anemia: Due to the reduced production of red blood cells, which can cause fatigue, weakness, and pallor.
  • Thrombocytopenia: A decrease in platelet count, which can lead to easy bruising and bleeding.
  • Neutropenia: A reduction in normal white blood cells, which increases the risk of infections.
  • Bone pain and bone marrow infiltration: The accumulation of leukemic blasts can cause bone pain and potential bone marrow infiltration, leading to organ dysfunction.

AML is further classified into subtypes based on the specific genetic abnormalities and the lineage of the leukemic cells. This classification is important for determining prognosis and guiding treatment decisions.

Clinical Presentation and Diagnosis

The clinical presentation of AML in children can vary depending on the extent of bone marrow involvement and the degree of organ infiltration. Common signs and symptoms include:

  • Fatigue and weakness
  • Pallor
  • Fever and recurrent infections
  • Easy bruising or bleeding
  • Bone pain
  • Abdominal discomfort or swelling (due to an enlarged spleen or liver)
  • Shortness of breath
  • Neurological symptoms (e.g., headaches, seizures, or changes in mental status)

The diagnosis of AML is typically made through the following tests:

  • Complete blood count (CBC): This test will reveal abnormal levels of white blood cells, red blood cells, and platelets.
  • Bone marrow aspiration and biopsy: This procedure involves obtaining a sample of bone marrow, typically from the hip bone, for examination under a microscope to identify the presence of leukemic blasts and their specific characteristics.
  • Cytogenetic and molecular genetic tests: These tests analyze the genetic abnormalities present in the leukemic cells, which can help determine the subtype of AML and guide treatment decisions.
  • Additional tests: Depending on the clinical presentation, additional tests may be performed, such as lumbar puncture (to check for central nervous system involvement), imaging studies (e.g., CT or MRI scans), or organ function tests.

Treatment

The treatment of AML in children typically involves a combination of chemotherapy and, in some cases, stem cell transplantation. The specific treatment approach depends on various factors, including the subtype of AML, the risk stratification, and the patient's overall health status.

Chemotherapy

Chemotherapy is the primary treatment modality for AML in children. The treatment typically involves two phases:

  1. Induction chemotherapy: This phase aims to achieve complete remission by destroying the leukemic cells in the bone marrow and blood. Common chemotherapy regimens used for induction include a combination of cytarabine and an anthracycline (e.g., daunorubicin or idarubicin).
  2. Consolidation chemotherapy (post-remission therapy): Once remission is achieved, consolidation chemotherapy is given to eliminate any remaining leukemic cells and prevent relapse. This phase may involve intensive chemotherapy regimens, stem cell transplantation, or a combination of both.

Stem Cell Transplantation

Stem cell transplantation, also known as bone marrow transplantation, may be recommended for certain high-risk or relapsed cases of AML in children. There are two main types of stem cell transplantation:

  • Allogeneic stem cell transplantation: In this procedure, the patient receives stem cells from a matched donor, typically a sibling or an unrelated donor. This approach has a higher risk of complications, such as graft-versus-host disease (GVHD), but also offers a potential graft-versus-leukemia effect, which can help eliminate residual leukemic cells.
  • Autologous stem cell transplantation: In this procedure, the patient's own stem cells are collected, stored, and then reinfused after high-dose chemotherapy or radiation therapy has been administered. This approach is associated with a lower risk of GVHD but may have a higher risk of relapse compared to allogeneic transplantation.

The decision to pursue stem cell transplantation is based on various factors, including the patient's risk stratification, cytogenetic and molecular abnormalities, response to induction chemotherapy, and availability of a suitable donor.

Supportive Care

In addition to chemotherapy and stem cell transplantation, supportive care measures are essential for managing the complications of AML and its treatment. These may include:

  • Blood product transfusions (e.g., red blood cells, platelets) to manage anemia and thrombocytopenia
  • Antibiotics and antifungal medications to prevent and treat infections
  • Growth factors (e.g., granulocyte colony-stimulating factor, G-CSF) to stimulate the production of white blood cells
  • Nutritional support and pain management
  • Psychosocial support for the patient and family

Prognosis and Long-term Follow-up

The prognosis for AML in children has improved significantly in recent decades due to advancements in treatment approaches and supportive care. However, the prognosis can vary widely depending on several factors, including:

  • Age at diagnosis: Younger children tend to have a better prognosis compared to older children and adolescents.
  • Cytogenetic and molecular abnormalities: Certain genetic abnormalities are associated with better or worse outcomes.
  • Response to induction chemotherapy: Patients whoachieve complete remission after induction chemotherapy generally have a more favorable prognosis.

Long-term follow-up and monitoring are crucial for children treated for AML, as they are at an increased risk of developing potential late effects and secondary malignancies. Regular follow-up visits, laboratory tests, and imaging studies may be recommended to monitor for potential complications, such as:

  • Cardiotoxicity: Certain chemotherapeutic agents and radiation therapy can potentially cause long-term effects on the heart, leading to conditions like cardiomyopathy or congestive heart failure.
  • Pulmonary complications: Chemotherapy and radiation therapy can increase the risk of developing lung diseases, such as pulmonary fibrosis or restrictive lung disease.
  • Endocrine and metabolic disorders: Treatment for AML can affect the normal functioning of the endocrine system, leading to conditions like growth hormone deficiency, thyroid dysfunction, or impaired fertility.
  • Neurocognitive and developmental delays: Chemotherapy, radiation therapy, and the disease itself can impact neurocognitive function and development, particularly in younger children.
  • Secondary malignancies: Survivors of AML are at an increased risk of developing secondary cancers later in life, such as myelodysplastic syndromes, acute lymphoblastic leukemia, or solid tumors.

Regular monitoring, appropriate screening, and timely intervention are crucial for managing and mitigating these potential long-term effects. Survivors of childhood AML may require multidisciplinary care involving pediatric oncologists, endocrinologists, cardiologists, psychologists, and other specialists to ensure optimal long-term outcomes and quality of life.

Further Reading

Tags:

Powered by Blogger.